|
Sign In to gain access to subscriptions and/or personal tools.
|
Management of Hepatitis C Infection in the HIV-Infected Patient
Kelly McNelis, BS, PharmD
Christiana Care Health Services–Wilmington Hospital Annex, HIV Community Program Room 221, PO Box 1668, Wilmington, DE19899-1668; kmcnelis{at}christianacare.org
Morbidity and mortality associated with HIV infection have rapidly decreased with the introduction of highly active antiretroviral therapy. Of recent concern is the increase of unusual opportunistic infections, particularly hepatitis C virus in this population. Because of the shared route of transmission, a significant number of HIV-infected patients are also coinfected with hepatitis C virus. HIV infection has been demonstrated to increase the rate of hepatitis C virus disease progression. New data on the use of pegylated interferon plus ribavirin indicate that while cure of hepatitis C virus in the coinfected patient is a clinical challenge, it is possible. Aggressive management of anemia, drug-induced depression, and drug interactions increase the opportunity for clinical response and positive patient outcomes.
Key Words: Pegylated interferon • ribavirin • hepatitis C virus • liver biopsy • fibrosis
References
Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 t-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195.[Abstract/Free Full Text] Palella FJ Jr, Delany KM, Moorman AC, et al. Decliningmorbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.[Abstract/Free Full Text]SulkowskiMS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.[Abstract/Free Full Text]Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections amongHIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2004;53:1-112.[Medline]
[Order article via Infotrieve]Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 suppl 1):S30-S34.[Web of Science][Medline]
[Order article via Infotrieve]National Institutes ofHealth. NIH ConsensusDevelopment Conference Statement: management of hepatitis C. Gastroenterology. 2002;123:2082-2099.[CrossRef][Medline]
[Order article via Infotrieve]Garfein RS, Vlahov D, GalaiN, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.[Abstract/Free Full Text]Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. Alongitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol. 1993;9:255-262.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]SulkowskiMS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30:S77-S84.[Medline]
[Order article via Infotrieve]Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989:244;359-362.[Abstract/Free Full Text]Dieterich DT, Kontorinis N, Agarwal K. HIV/HCV coinfection in clinical practice. J Int Assoc Physicians AIDS Care. 2004;3:S4-S14.Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management and treatment of hepatitis C. Hepatology. 2004:39;1147-1171.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]EysterME, AlterHJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991;115:764-768.[Abstract/Free Full Text]AIDSinfo. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected withhumanimmunodeficiency virus. November 28, 2001. Available at: http://www.aidsinfo.nih.gov. Accessed May 25, 2005.Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis. 1997;176:414-420.[Web of Science][Medline]
[Order article via Infotrieve]US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50:1-52.[Medline]
[Order article via Infotrieve]Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559-568.[CrossRef][Medline]
[Order article via Infotrieve]Lanphear BP, Linneman CC Jr, Cannon CG, De Ronde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994;15:745-750.[Web of Science][Medline]
[Order article via Infotrieve]Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997;102:S9-S15.[CrossRef]Winnock M, Salmon-Ceron D, Dabis F, Chene G. Interaction between HIV-1 and HCV infections: towards a new entity? J Antimicrob Chemother. 2004;53:936-946.[Abstract/Free Full Text]Seeff LB, Buskell-Bales Z, Wright EC. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992;327:1906-1911.[Abstract]Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-termfollow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Alter MJ, Margolis HS, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-1905.[Abstract]Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher viral levels of hepatic HCV RNA. J Viral Hepat. 1999;6:203-208.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Thomas DL, Shih JW, Alter HJ. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996;174:690-695.[Web of Science][Medline]
[Order article via Infotrieve]Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis. 2000;181:844-851.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-1471.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Bach N, Thelse ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis. 1992;12:205-212.[Web of Science][Medline]
[Order article via Infotrieve]DorrucciM, Valdarchi C, Suligoi B, et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS. 2004;18:2313-2318.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis. 1995;172:1503-1508.[Web of Science][Medline]
[Order article via Infotrieve]Piroth L, DuongM, Quantin C. Does hepatitisCvirus coinfection accelerate clinical and immunological evolution ofHIV-infected patients? AIDS. 1998;12L381-388.[Web of Science][Medline]
[Order article via Infotrieve]AIDSinfo. Guidelines for the use antiretroviral agents in HIV-1-infected adults and adolescents. April 7, 2005. Available at: http://www.aidsinfo.nih.gov. Accessed May 22, 2005.Alberi A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42:615-624.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.[CrossRef][Medline]
[Order article via Infotrieve]Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.[Web of Science][Medline]
[Order article via Infotrieve]Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]DiMartinoV, Rufat P, BoyerN. The influence ofhumanimmunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Bhattacharya R, Shuhart M. Hepatitis C and alcohol: interactions, outcomes and implications. J Clin Gastroenterol. 2003;36:242-252.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:196-204.[Free Full Text]Hadler SC. Hepatitis B prevention and human immunodeficiency virus infection. Ann Intern Med. 1998;109:92-94.Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and --uninfected homosexual men. J Infect Dis. 1997;176:1064-1067.[Web of Science][Medline]
[Order article via Infotrieve]Chung RT, Anderson J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.[Abstract/Free Full Text]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.[Abstract/Free Full Text]Hadziyannis SJ, SetteHJr, Morgan TR. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.[Abstract/Free Full Text]LagunoM, Murrillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36.[Web of Science][Medline]
[Order article via Infotrieve]Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc. 2004;292:2839-2848.[Abstract/Free Full Text]Manns MP, Wedemeyer H. Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. J Am Med Assoc. 2004;292:2909-2913.[Free Full Text]PEG-Intron and Rebetol [package insert]. Kenilworth, NJ: Schering Corporation; 2005.PEGASYS and COPEGUS [package insert]. Nutley, NJ: Roche Laboratories; 2005.Romero M, Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Management of chronic hepatitis C in patients co-infected with HIV. Drug Safety. 2004;27:7-24.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Cesario K, Khandwala F, Edwards K, CareyW, Barnes D, ZeinN. Impact of obesity on degree of liver disease and response to therapy in patientswith chronic hepatitisCgenotype 1 infection. Paper presented at: Digestive Diseases Week Meeting; May 14-19, 2005; Chicago, Ill. Presentation M953.Schering-Plough. Available at: http://www.sch-plough.com/schering_plough/pc/patientprograms.jsp. Accessed April 21, 2005.Pegasys. Available at: http://www.pegasys.com/.Accessed April 21, 2005.Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Applied Psychological Measurement. 1977;3:385-401.TurveCL, WallaceRB, HerzogR. ArevisedCES-Dmeasure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr. 1999;11:139-148.[CrossRef][Medline]
[Order article via Infotrieve]Mayfield DG, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. J Psychiatry. 1974;131:1121-1123.Hepatitis Resource Network. Available at: http://www.h-r-n.org. Accessed April 21, 2005.Pockros PJ, ShiffmanML, Schiff ER, et al. Epoetin alfa improves quality of life in anemia HCV-infected patients receiving combination therapy. Hepatology. 2004;40:1450-1458.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005;39:S3-S8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Re VL, Kostman JR. Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Reader. 2004;14:555-571.[Medline]
[Order article via Infotrieve]Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clerq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2 •,3 •-dideoxynucleosides but enhances inhibitory effects of purine 2 •,3 •-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agents Chemother. 1987;31:1613-1617.[Abstract/Free Full Text]Alvarez D, Dieterich DT, Moorehead L, Ball L, Sulkowski MS, and the Hepatitis Resource Network Clinical Trials Group. Impact of zidovudine on anemia and epoetin-alfa use during pegylated interferon and ribavirin therapy for HCV in HIV-infected patients. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. Poster 927.
Journal of Pharmacy Practice, Vol. 19, No. 1,
37-52 (2006)
DOI: 10.1177/0897190005284096
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
